Lukang Pharmaceutical (600789.SH) subsidiary obtained finasteride tablet registration certificate

Zhitong Finance App News, Lu Kang Pharmaceutical (600789.SH) issued an announcement. Recently, Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (“Sete”), the holding subsidiary of the company, received the “Drug Registration Certificate” (approval number: 2025S03900, 2025S03901) for finasteride tablets issued by the State Drug Administration. The drug is a generic drug approved in 4 categories according to the new registration classification, and is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs.

Finasteride is a synthetic steroidal compound that is a specific inhibitor of the intracellular enzyme type II 5α reductase during the metabolism of the androgen testosterone to dihydrotestosterone (DHT). Benign prostatic hyperplasia (BPH), or prostatic hypertrophy, depends on the conversion of testosterone to DHT in the prostate. This product is very effective in reducing DHT in the blood and prostate. The 1mg specification of this product is suitable for treating male baldness (androgenic alopecia), and can promote hair growth and prevent continued hair loss; the 5mg specification is suitable for treating and controlling benign prostatic hyperplasia (BPH) and preventing urinary system events. This product can shrink an enlarged prostate, improve urinary flow, and improve symptoms related to prostate hyperplasia.